Regulatory Relief
The regulatory burden faced by hospitals is substantial and unsustainable.
Every day, hospitals, health systems and post-acute care providers confront the daunting task of complying with a growing number of federal regulations. They are constantly challenged to understand and implement new or revised regulations, while maintaining their core mission of providing high-quality patient care.
Providers appreciate that federal regulation is intended to ensure that health care patients receive safe, high-quality care, and prioritize it as a critical part of their day-to-day work.
But the scope and pace of the changes being made is out-stripping many providers’ ability to absorb them. At the same time, many of these regulations do not improve the quality of patient care or access to services.
Providers need relief now. Read on for more information and resources on the AHA's regulatory relief agenda.
The Department of Health and Human Services (HHS) May 13 announced a 60-day public comment period for stakeholders regarding its RFI to remove outdated or unnecessary regulations.
The AHA provides an overview of the key statutes and regulations that have impeded competition in the health care market and offer a series of recommendations to remedy these obstacles.
AHA May 23 submitted recommendations to the Department of Justice and Federal Trade Commission in response to the agencies’ requests for information on unnecessary or burdensome anticompetitive regulations.
The AHA provides an overview of the key statutes and regulations that have impeded competition in the health care market and offer a series of recommendations to remedy these obstacles.
The AHA May 12 responded to the Office of Management and Budget's April 11 request for information on regulatory relief, making 100 suggestions to the Trump administration to help reduce burden on hospitals and health systems.
AHA responds to the Office of Management and Budget Deregulation Request for Information.
The Trump administration May 5 issued two executive orders on pharmaceutical manufacturing and life-sciences research.
Directs the Commissioner of the Food and Drug Administration to review and eliminate any duplicative or unnecessary requirements in regulations and guidance pertaining to the development of domestic pharmaceutical manufacturing within 180 days.
The Centers for Medicare & Medicaid Services today released a notice seeking public comment on the collection of information request regarding the State Plan Amendment template for medication-assisted treatment. SPA templates are provided by CMS to assist states with Medicaid application…
The Trump administration April 9 released a series of executive orders (EOs) and took other administrative actions aimed at reducing regulatory burden.